Chargement en cours...
EUS fine-needle pancreatic core biopsy can determine eligibility for tumor-agnostic immunotherapy
Background and study aims The US FDA recently approved a cancer treatment with pembrolizumab based upon the tumor biomarker status of deficient mismatch repair (dMMR) rather than a specific disease-based approach. We sought to determine if endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) c...
Enregistré dans:
| Publié dans: | Endosc Int Open |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
© Georg Thieme Verlag KG
2018
|
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6175678/ https://ncbi.nlm.nih.gov/pubmed/30302387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/a-0650-4447 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|